Personal meaningfulness of potential FDA-approved treatments: Perspectives of individuals living with Alzheimer's disease

With the emergence of new clinical trial data on disease-modifying therapies in several. Alzheimer's disease (AD) studies, the Alzheimer's Association convened individuals living with AD to gain their perspective on meaningfulness and new treatments. A total of 30 Alzheimer's Association National Early Stage Advisory Group members participated in a focus group or an online survey to gain insights on what is wanted from a first-in-class treatment that could stop the progression of their disease at the earliest stage. Participants felt that researchers and regulators need to consider personal meaningfulness alongside clinical meaningfulness. At the same time, individuals living with AD felt that access, education, choice, and affordability were all important considerations moving forward.

Automated summary

With the emergence of new clinical trial data on disease-modifying therapies in Alzheimer's disease (AD) studies, the Alzheimer's Association sought the perspectives of individuals living with AD on significance and new treatments. Thirty members of the Alzheimer's Association's National Early Stage Advisory Group participated in a focus group or online survey to gain insights on their desires for a groundbreaking treatment that could halt the progression of their disease at an early stage. Participants emphasized the importance of considering personal significance in addition to clinical significance and highlighted the need for accessibility, education, choice, and affordability moving forward.